ATE269091T1 - Verfahren zur regulierung des vagaltonus - Google Patents

Verfahren zur regulierung des vagaltonus

Info

Publication number
ATE269091T1
ATE269091T1 AT96944882T AT96944882T ATE269091T1 AT E269091 T1 ATE269091 T1 AT E269091T1 AT 96944882 T AT96944882 T AT 96944882T AT 96944882 T AT96944882 T AT 96944882T AT E269091 T1 ATE269091 T1 AT E269091T1
Authority
AT
Austria
Prior art keywords
vagal tone
patient
regulating
regulating vagal
tone
Prior art date
Application number
AT96944882T
Other languages
German (de)
English (en)
Inventor
Amir Pelleg
Original Assignee
Duska Scient Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duska Scient Co filed Critical Duska Scient Co
Application granted granted Critical
Publication of ATE269091T1 publication Critical patent/ATE269091T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrophonic Musical Instruments (AREA)
  • Measuring And Recording Apparatus For Diagnosis (AREA)
  • Electrotherapy Devices (AREA)
  • Reverberation, Karaoke And Other Acoustics (AREA)
AT96944882T 1995-12-26 1996-12-24 Verfahren zur regulierung des vagaltonus ATE269091T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US922895P 1995-12-26 1995-12-26
US08/771,518 US5874420A (en) 1995-12-26 1996-12-23 Process for regulating vagal tone
PCT/US1996/020255 WO1997023218A1 (en) 1995-12-26 1996-12-24 A process for regulating vagal tone

Publications (1)

Publication Number Publication Date
ATE269091T1 true ATE269091T1 (de) 2004-07-15

Family

ID=26679226

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96944882T ATE269091T1 (de) 1995-12-26 1996-12-24 Verfahren zur regulierung des vagaltonus

Country Status (7)

Country Link
US (1) US5874420A (enExample)
EP (1) EP0906102B1 (enExample)
JP (1) JP2002518983A (enExample)
AT (1) ATE269091T1 (enExample)
AU (1) AU710770B2 (enExample)
DE (1) DE69632743T2 (enExample)
WO (1) WO1997023218A1 (enExample)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6449507B1 (en) * 1996-04-30 2002-09-10 Medtronic, Inc. Method and system for nerve stimulation prior to and during a medical procedure
US7225019B2 (en) 1996-04-30 2007-05-29 Medtronic, Inc. Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure
US7269457B2 (en) * 1996-04-30 2007-09-11 Medtronic, Inc. Method and system for vagal nerve stimulation with multi-site cardiac pacing
US20040199209A1 (en) * 2003-04-07 2004-10-07 Hill Michael R.S. Method and system for delivery of vasoactive drugs to the heart prior to and during a medical procedure
US6628987B1 (en) * 2000-09-26 2003-09-30 Medtronic, Inc. Method and system for sensing cardiac contractions during vagal stimulation-induced cardiopalegia
US6532388B1 (en) 1996-04-30 2003-03-11 Medtronic, Inc. Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure
US6735471B2 (en) 1996-04-30 2004-05-11 Medtronic, Inc. Method and system for endotracheal/esophageal stimulation prior to and during a medical procedure
US6904318B2 (en) * 2000-09-26 2005-06-07 Medtronic, Inc. Method and system for monitoring and controlling systemic and pulmonary circulation during a medical procedure
US8036741B2 (en) 1996-04-30 2011-10-11 Medtronic, Inc. Method and system for nerve stimulation and cardiac sensing prior to and during a medical procedure
US6372724B1 (en) 1997-03-25 2002-04-16 Duska Scientific Co. Modulation of human mast cell activation
US6479523B1 (en) * 1997-08-26 2002-11-12 Emory University Pharmacologic drug combination in vagal-induced asystole
US6043259A (en) * 1998-07-09 2000-03-28 Medicure Inc. Treatment of cardiovascular and related pathologies
CA2366602A1 (en) 1999-03-08 2000-09-14 Medicure Inc. Pyridoxal analogues for vitamin b-6 disorders
WO2001000273A1 (en) 1999-06-25 2001-01-04 Emory University Devices and methods for vagus nerve stimulation
CA2376029A1 (en) * 1999-07-13 2001-01-18 Medicure Inc. Use of pyridoxin derivatives for the treatment of diabetes and related complications
CA2383252A1 (en) * 1999-08-24 2001-03-01 Medicure International Inc. Treatment of cardiovascular related pathologies
US7442689B2 (en) * 2000-02-29 2008-10-28 Medicure International Inc. Cardioprotective phosphonates and malonates
PT1268498E (pt) 2000-02-29 2005-07-29 Medicure Int Inc Fosfonatos cardioprotectores
JP2003528146A (ja) 2000-03-28 2003-09-24 メディキュア インターナショナル インコーポレイテッド 脳血管疾患の治療
US6548519B1 (en) 2001-07-06 2003-04-15 Medicure International Inc. Pyridoxine and pyridoxal analogues: novel uses
US6897228B2 (en) * 2000-07-07 2005-05-24 Medicure International Inc. Pyridoxine and pyridoxal analogues: new uses
EP1299358B1 (en) 2000-07-07 2007-06-13 Medicure International Inc. Pyridoxine and pyridoxal analogues as cardiovascular therapeutics
US6487446B1 (en) * 2000-09-26 2002-11-26 Medtronic, Inc. Method and system for spinal cord stimulation prior to and during a medical procedure
US7369890B2 (en) * 2000-11-02 2008-05-06 Cardiac Pacemakers, Inc. Technique for discriminating between coordinated and uncoordinated cardiac rhythms
US6689117B2 (en) * 2000-12-18 2004-02-10 Cardiac Pacemakers, Inc. Drug delivery system for implantable medical device
US20040121988A1 (en) * 2001-03-28 2004-06-24 Medicure International Inc. Treatment of cerebrovascular disease
US6912420B2 (en) 2001-04-10 2005-06-28 Cardiac Pacemakers, Inc. Cardiac rhythm management system for hypotension
US20050283197A1 (en) * 2001-04-10 2005-12-22 Daum Douglas R Systems and methods for hypotension
US6907288B2 (en) 2001-04-10 2005-06-14 Cardiac Pacemakers, Inc. Cardiac rhythm management system adjusting rate response factor for treating hypotension
US6748271B2 (en) 2001-07-27 2004-06-08 Cardiac Pacemakers, Inc. Method and system for treatment of neurocardiogenic syncope
US7191000B2 (en) * 2001-07-31 2007-03-13 Cardiac Pacemakers, Inc. Cardiac rhythm management system for edema
US7006868B2 (en) * 2002-03-06 2006-02-28 Pacesetter, Inc. Method and apparatus for using a rest mode indicator to automatically adjust control parameters of an implantable cardiac stimulation device
US6968232B2 (en) * 2002-03-06 2005-11-22 Pacesetter, Inc. Method and apparatus for using a rest mode indicator to automatically adjust control parameters of an implantable cardiac stimulation device
US20030232887A1 (en) * 2002-04-10 2003-12-18 Johnson Douglas Giles Preparation and use of a stable formulation of allosteric effector compounds
JP4473491B2 (ja) * 2002-05-28 2010-06-02 株式会社資生堂 毛穴縮小剤
US7089055B2 (en) 2002-06-28 2006-08-08 Cardiac Pacemakers, Inc. Method and apparatus for delivering pre-shock defibrillation therapy
US7226422B2 (en) 2002-10-09 2007-06-05 Cardiac Pacemakers, Inc. Detection of congestion from monitoring patient response to a recumbent position
US7627373B2 (en) * 2002-11-30 2009-12-01 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
US20040158289A1 (en) * 2002-11-30 2004-08-12 Girouard Steven D. Method and apparatus for cell and electrical therapy of living tissue
US20040161481A1 (en) * 2002-12-18 2004-08-19 Algorx Administration of capsaicinoids
US20050019436A1 (en) * 2002-12-18 2005-01-27 Algorx Injectable capsaicin
US20040186077A1 (en) * 2003-03-17 2004-09-23 Medicure International Inc. Novel heteroaryl phosphonates as cardioprotective agents
EA008705B1 (ru) * 2003-04-08 2007-06-29 Алгоркс Фармасьютикалз, Инк. Получение и очистка синтетического капсаицина
US20070259966A1 (en) * 2004-04-22 2007-11-08 Allos Therapeutics, Inc. Coadministration of Radiation, Efaproxiral Sodium, and Supplemental Oxygen for the Treatment of Cancer
US20100099630A1 (en) * 2004-04-29 2010-04-22 Maccarter Dean J Method for improving ventilatory efficiency
JPWO2005107804A1 (ja) * 2004-05-06 2008-03-21 小野薬品工業株式会社 呼吸器疾患治療剤
AU2005259735A1 (en) * 2004-07-07 2006-01-12 Medicure International Inc. Combination therapies employing platelet aggregation drugs
CA2573565A1 (en) * 2004-07-22 2006-02-02 Duska Scientific Co. Method of diagnosing, monitoring and treating pulmonary diseases
US20070060549A1 (en) * 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
US7387610B2 (en) * 2004-08-19 2008-06-17 Cardiac Pacemakers, Inc. Thoracic impedance detection with blood resistivity compensation
CA2585165A1 (en) 2004-10-28 2006-05-18 Medicure International Inc. Dual antiplatelet/anticoagulant pyridoxine analogs
US20060094749A1 (en) * 2004-10-28 2006-05-04 Medicure International Inc. Substituted pyridoxines as anti-platelet agents
US7459468B2 (en) * 2004-10-28 2008-12-02 Medicure International, Inc. Aryl sulfonic pyridoxines as antiplatelet agents
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
US8060219B2 (en) * 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US7603170B2 (en) * 2005-04-26 2009-10-13 Cardiac Pacemakers, Inc. Calibration of impedance monitoring of respiratory volumes using thoracic D.C. impedance
US7907997B2 (en) * 2005-05-11 2011-03-15 Cardiac Pacemakers, Inc. Enhancements to the detection of pulmonary edema when using transthoracic impedance
US7340296B2 (en) 2005-05-18 2008-03-04 Cardiac Pacemakers, Inc. Detection of pleural effusion using transthoracic impedance
MX2008002733A (es) * 2005-09-01 2008-03-26 Hoffmann La Roche Diaminopirimidinas como moduladores p2x3 y p2x2/3.
AU2006317440A1 (en) * 2005-11-28 2007-05-31 Medicure International Inc. Selected dosage for the treatment of cardiovascular and related pathologies
US8343049B2 (en) 2006-08-24 2013-01-01 Cardiac Pacemakers, Inc. Physiological response to posture change
US8639327B2 (en) 2010-04-29 2014-01-28 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US8620425B2 (en) 2010-04-29 2013-12-31 Medtronic, Inc. Nerve signal differentiation in cardiac therapy
US8423134B2 (en) 2010-04-29 2013-04-16 Medtronic, Inc. Therapy using perturbation and effect of physiological systems
US8718763B2 (en) 2011-01-19 2014-05-06 Medtronic, Inc. Vagal stimulation
US8706223B2 (en) 2011-01-19 2014-04-22 Medtronic, Inc. Preventative vagal stimulation
US8781582B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
US8781583B2 (en) 2011-01-19 2014-07-15 Medtronic, Inc. Vagal stimulation
US8725259B2 (en) 2011-01-19 2014-05-13 Medtronic, Inc. Vagal stimulation

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4673563A (en) * 1980-10-14 1987-06-16 The University Of Virginia Alumni Patents Foundation Adenosine in the treatment of supraventricular tachycardia
US5049372A (en) * 1982-07-13 1991-09-17 Eliezer Rapaport Anticancer activities in a host by increasing blood and plasma adenosine 5'-triphosphate (ATP) levels
JP2783880B2 (ja) * 1989-11-24 1998-08-06 富士レビオ株式会社 心臓病治療剤
US5504090A (en) * 1994-03-30 1996-04-02 Trustees Of The University Of Pennsylvania Compositions and methods for the prevention and treatment of ischemia-reperfusion organ injury

Also Published As

Publication number Publication date
JP2002518983A (ja) 2002-06-25
EP0906102A4 (enExample) 1999-04-07
DE69632743D1 (de) 2004-07-22
AU710770B2 (en) 1999-09-30
WO1997023218A1 (en) 1997-07-03
US5874420A (en) 1999-02-23
DE69632743T2 (de) 2005-07-07
EP0906102A1 (en) 1999-04-07
AU1338397A (en) 1997-07-17
EP0906102B1 (en) 2004-06-16

Similar Documents

Publication Publication Date Title
DE69632743D1 (de) Verfahren zur regulierung des vagaltonus
DE69736712D1 (de) Verfahren zur milderung von neuropatischen schmerz mit prosaposin verwandten peptiden
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
GB9514451D0 (en) Sustained-release formulation
AU6602296A (en) Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
DE60027732D1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
DE69830178D1 (de) Wirstoffmischung in vagal-induzierter asystolie
DE69815090D1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE198830T1 (de) Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems
DE69616376D1 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
DE59611341D1 (de) Verwendung von saccharid-konjugaten
AU1520195A (en) Use of anti-tnf antibodies as drugs in treating diseases involving elevated interleukin-6 serum levels
ATE539795T1 (de) Stimulation tiefer gehirnbereiche
DE69535264D1 (de) Verfahren zur behandlung von diabetes mittels kgf
DE69635304D1 (de) Faenger fuer oxidantien
EP1098642A4 (en) METHODS OF TREATING MODULATED CONDITIONS WITH LACTOSYLCERAMIDE
ES8801760A1 (es) Un aparato de comunicaciones audioneurales para estimular los nervios sensoriales tactiles de una persona sorda.
DE69739970D1 (de) Methode zur behandlung sexueller fehlfunktionen
ATE304855T1 (de) Verwendung von olanzapin zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen
DE3861445D1 (de) Verfahren zur destillativen reinigung von tetrahydrofuran.
ATE297722T1 (de) Verwendung von gaba analoga wie gabapentin zur herstellung eines medikaments für die behandlung von entzündungserkrankungen
DE69619187D1 (de) Verfahren zur behandlung von motorischen defiziten
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
DE69736180D1 (de) Behandlung von manischen erkrankungen
ATE114468T1 (de) Ethyl-(+)-apovincaminat zur behandlung der demyelinisierung klinischer erscheinungen autoimmunen ursprungs.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties